Analysed TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ) News Sources
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
18-08-2026
marketbeat.com
TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial
10-05-2026
yahoo.com
TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...
13-05-2026
yahoo.com
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
10-06-2026
yahoo.com
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ...
07-08-2026
yahoo.com
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
31-08-2026
yahoo.com
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
22-09-2026
yahoo.com
TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance
23-09-2026
advfn.com
What is the current price of TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ)?
The current price of TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ) is $3.8.
TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ) absolute price change since previous trading day?
The absolute price change of TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ) since the previous trading day is $0.18.
TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ) percentage price change since previous trading day?
The percentage price change of TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ) since the previous trading day is 4.9724%.
What is the most recent average sentiment score for TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ)?
The most recent average sentiment score for TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ)?
The most recent sentiment for TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ) is .
SEC-8K** Filing Available For TRISALUS LIFE SCIENCES INC (TLSI:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.